Related Experiment Video
Updated: Feb 8, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools
Published on: December 28, 2021
Molecularly-driven precision medicine for advanced bladder cancer
Laura-Maria Krabbe1,2, Vitaly Margulis3, Andres Jan Schrader4
1Department of Urology, The University of Muenster Medical Center, Albert-Schweitzer, Campus 1, GB A1, 48149, Muenster, Germany. Lauramaria.Krabbe@ukmuenster.de.
Abstract:
Urothelial carcinoma of the bladder is a heterogeneous disease with many challenges for clinicians and patients alike. However, for the most part of the last three decades, treatment and outcomes for patients with this disease have not changed a lot. With recent advances in immunooncology leading to the approval of multiple agents for the metastatic setting, the treatment landscape started to change. With the emergent data from landmark multi-institutional sequencing projects as well as molecular data from recent trials, our understanding of the underlying disease biology, response patterns as well as definition of molecular subtypes has evolved tremendously. This review aims to summarize the currently available concepts of mutational profiles and molecular subtypes as well as their implications for management of urothelial carcinoma.
Insights
Urothelial carcinoma of the bladder treatment is evolving due to immunotherapy advances. Understanding molecular subtypes and mutational profiles is key for improved patient management and outcomes in this complex cancer.
Area of Science:
- Oncology
- Genetics
- Immunology
Background:
- Urothelial carcinoma of the bladder has shown limited treatment progress over the past three decades.
- Recent immunotherapy approvals offer new hope for metastatic disease.
- Advances in molecular profiling are reshaping our understanding of bladder cancer biology.
Purpose of the Study:
- To review current knowledge on mutational profiles and molecular subtypes of urothelial carcinoma.
- To discuss the implications of these molecular characteristics for clinical management.
- To highlight recent advances in understanding bladder cancer heterogeneity.
Main Methods:
- Review of recent clinical trials and multi-institutional sequencing projects.
- Analysis of emergent data on molecular subtypes and response patterns.
- Synthesis of current concepts in urothelial carcinoma biology.
Main Results:
- Significant evolution in understanding bladder cancer's molecular landscape.
- Identification of distinct molecular subtypes influencing disease behavior.
- Emerging data linking specific mutational profiles to treatment response.
Conclusions:
- Molecular profiling is crucial for personalized urothelial carcinoma treatment.
- Understanding subtypes can guide therapeutic strategies and predict outcomes.
- Continued research into bladder cancer biology is essential for further advancements.
Related Concept Videos
Urinary Bladder
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
Uncertainty in Measurement: Accuracy and Precision
Microorganisms in Medicine and Therapeutics
Molecular Models
Accuracy and Precision
Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.

